Next-Generation Antibody Therapeutics Market 2013-2023
Therapeutic antibody technologies - find developments and commercial prospects
Where are therapeutic antibodies heading? Visiongain's updated report gives you revenue predictions to 2023. There you see sales data, R&D trends, outlooks and opportunities.
You find the potential of monoclonal antibodies (mAbs) and other immunotechnology. See forecasted sales at overall world market and submarket level. Also assess emerging trends and expected products. Many opportunities remain - you discover the areas to prosper.
Forecasts to 2023 and other analyses show you the greatest commercial potentials
In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis, business news, prospects and developmental trends (R&D). You receive 54 tables, 34 charts and two research interviews.
Our work lets you investigate the most promising and lucrative areas of that biopharma market, helping you stay ahead in knowledge. Reduce the risk of being left behind.
Emerging antibody technologies (platforms) hold great promise. The following sections show how you discover their future.
Find prospects for the world market and submarkets
Our report shows you revenue forecasts to 2023 for these overall world markets:
Demand for those biological drugs (biologics) increases and many products await launch. Find how high revenues can go, discovering segments and years with highest predicted growth.
You see what's happening, understanding trends, challenges and opportunities. From 2013 to 2023, that field will contribute much to the pharmaceutical industry. You find the commercial potential.
Our work also analyses the main developmental areas.
Research and development - assess innovation, trends and possibilities
For immunotherapies, what's happening in R&D? You see trends and outlooks there -engineering of antibodies and related agents:
For large companies and specialty pharma firms there exist many opportunities. Our work explains, covering many issues.
What affects therapeutic vaccine technology from 2013?
Our report discusses issues and events affecting that industry and market from 2013:
Leading companies and 2015 market value
What happens next? We predict the world market for therapeutic antibodies will reach $69.6bn in 2015, and expand further to 2023.
From 2013, next-generation technologies will gain rising market shares and high revenues. Those drugs hold great scope for investment, technological advances and commercial success. Our study shows you how they progress.
You see what products and organisations hold greatest potential. Our work explores these leading companies:
Eight ways Next-Generation Antibody Therapeutics Market 2013-2023 helps
In particular, then, our investigation gives you the following knowledge:
That work gives independent analysis. You receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.
Our knowledge costs only a tiny fraction of potential profits from your understanding that expanding market. See what it holds and what you can gain.
Discover prospects to 2023 by ordering now
Visiongain's investigation is for everyone needing forward-looking analysis of antibodies and related biologics. You find data, trends and predictions. Please order our report now.
Where are therapeutic antibodies heading? Visiongain's updated report gives you revenue predictions to 2023. There you see sales data, R&D trends, outlooks and opportunities.
You find the potential of monoclonal antibodies (mAbs) and other immunotechnology. See forecasted sales at overall world market and submarket level. Also assess emerging trends and expected products. Many opportunities remain - you discover the areas to prosper.
Forecasts to 2023 and other analyses show you the greatest commercial potentials
In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis, business news, prospects and developmental trends (R&D). You receive 54 tables, 34 charts and two research interviews.
Our work lets you investigate the most promising and lucrative areas of that biopharma market, helping you stay ahead in knowledge. Reduce the risk of being left behind.
Emerging antibody technologies (platforms) hold great promise. The following sections show how you discover their future.
Find prospects for the world market and submarkets
Our report shows you revenue forecasts to 2023 for these overall world markets:
- Therapeutic antibodies (overall sales)
- Next-generation therapeutic antibodies.
- Engineered antibodies
- Antibody-drug conjugates (ADCs)
- Bispecific antibodies (bisAbs)
- Antibody fragments and antibody-like proteins
- Biosimilar antibody products.
Demand for those biological drugs (biologics) increases and many products await launch. Find how high revenues can go, discovering segments and years with highest predicted growth.
You see what's happening, understanding trends, challenges and opportunities. From 2013 to 2023, that field will contribute much to the pharmaceutical industry. You find the commercial potential.
Our work also analyses the main developmental areas.
Research and development - assess innovation, trends and possibilities
For immunotherapies, what's happening in R&D? You see trends and outlooks there -engineering of antibodies and related agents:
- Glycoengineering and Fc amino acid mutations
- New antibodies against CD20, HER2 and EGFR targets
- Immunoconjugates
- Dual ligand systems and other multispecific approaches.
- Recombinant antibody mixtures
- Bispecific T-cell Engagers (BiTEs)
- Designated Ankyrin Repeat Proteins (DARTs)
- Domain antibodies, scFvs and other next-generation fragments
- Anticalins, Adnectins and other alternative scaffolds.
For large companies and specialty pharma firms there exist many opportunities. Our work explains, covering many issues.
What affects therapeutic vaccine technology from 2013?
Our report discusses issues and events affecting that industry and market from 2013:
- Fusion proteins and other variations on the mAb theme
- Targets for new treatments
- Oncology - the main focus, especially treating solid tumours
- Treatment of other cancers, arthritis, osteoporosis and ophthalmic disorders
- Challenges affecting producers of biosimilars.
- Fragments vs antibody-like protein
- Companion diagnostics and personalised medicine
- Improvement of biologics - biobetters
- Entry barriers to the antibody technology market.
Leading companies and 2015 market value
What happens next? We predict the world market for therapeutic antibodies will reach $69.6bn in 2015, and expand further to 2023.
From 2013, next-generation technologies will gain rising market shares and high revenues. Those drugs hold great scope for investment, technological advances and commercial success. Our study shows you how they progress.
You see what products and organisations hold greatest potential. Our work explores these leading companies:
- Roche
- Kyowa Hakko Kirin
- Bristol-Myers Squibb
- MedImmune
- BioWa
- Seattle Genetics
- ImmunoGen.
- Amgen
- Pfizer
- Xencor
- Sanofi
- Bayer
- Biogen Idec.
Eight ways Next-Generation Antibody Therapeutics Market 2013-2023 helps
In particular, then, our investigation gives you the following knowledge:
- Revenues to 2023 for the world therapeutic antibodies market - you discover commercial prospects for immunotherapy
- Revenues to 2023 for the world next-generation antibodies market and five submarkets - you find sales prospects for emerging technologies
- Review of R&D - technology and disease areas - you hear about progress in research and development, assessing technological and clinical possibilities
- Discussions of companies - you find activities, products, capabilities and outlooks
- Interviews with authorities in the industry - you discover opinions and debates to help you stay ahead
- Understanding of competition and opportunities - you see what affects the industry, getting impressions of its future
- Discussions of what stimulates and restrains the industry and market - you assess challenges and strengths, helping you compete and gain advantages
- Prospects for established firms and those seeking to enter the sector - you explore needs, practices and outlooks for success.
That work gives independent analysis. You receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.
Our knowledge costs only a tiny fraction of potential profits from your understanding that expanding market. See what it holds and what you can gain.
Discover prospects to 2023 by ordering now
Visiongain's investigation is for everyone needing forward-looking analysis of antibodies and related biologics. You find data, trends and predictions. Please order our report now.
1. EXECUTIVE SUMMARY
1.1 Next-Generation Antibody Therapeutics: Market Overview
1.2 Contents of this Report
1.3 Research and Analysis Methods
2. ANTIBODY THERAPEUTICS, PAST, PRESENT AND FUTURE: CLINICAL AND COMMERCIAL OVERVIEW, 2013-2023
2.1 Antibody Therapeutics: Worth More Than $50bn in 2011
2.1.1 Can Antibody Therapeutic Growth Continue? Forecast for the Market, 2013-2023
2.1.2 Next-Generation Antibody Technologies: A Revolution in Waiting
2.1.3 Next-Generation Antibody Therapeutics Will Capture More than 10% of the Market by 2023
2.1.4 Which Segments Will Grow Fastest? Next-Generation Market Forecast Breakdown, 2011-2023
2.2 From First Discoveries to Full Humanisation: The Growth of the Antibody Market
2.2.1 Natural Antibodies: Key to the Immune System
2.2.2 From Serum Therapy to Monoclonal Antibodies (MAbs)
2.2.3 Humanising the MAb
2.2.4 Fabs, Fusion Proteins and Other Variations on the MAb Theme
2.3 The Next Generation Antibody Therapeutics Market: An Overview
2.3.1 Market Shares for Next-Generation Segments, 2011-2023
2.3.1.1 ADCs Lead the Way, 2011-2012
2.3.1.2 CAGR Over 100% for Three Segments, 2011-2016
2.3.1.3 Bispecific Antibodies to Reach 19% Market Shares by, 2017-2023
2.3.2 Next Generation Antibody Therapeutics: Product Analysis
2.3.2.1 Approved Next-Generation Antibody Therapeutics
2.3.2.2 More than 80 Products in Clinic
2.3.3 Oncology: The Major Focus
2.3.4 The Main Targets for Next-Generation Products
2.3.5 Regional Markets for Next-Generation Products
3. ENGINEERED ANTIBODIES MARKET, 2013-2023
3.1 Engineered Antibodies Market Forecast, 2013-2023
3.2 Engineered Antibodies: Overview of the Field in 2011
3.2.1 Antibody Optimisation is the Norm
3.2.2 Engineering for a Real Difference: CDC, ADCC and Half-Life
3.2.3 Ways to Engineer: Glycosylation and Amino Acid Mutations
3.2.4 What are the Platforms?
3.2.4.1 BioWa: Potelligent Removal of Fructose
3.2.4.2 Glycart: GlycoMAB for Extra ADCC
3.2.4.3 Xencor: XmAb Leads Amino Acid Modification Engineering Pipeline
3.2.5 The Pipeline for Engineered Antibodies, 2013
3.2.5.1 25 Candidates in Clinic, 2013
3.2.5.2 CD20 and HER Family Major Targets
3.2.5.3 Kyowa Hakko Kirin Largest Share of Pipeline by Volume
3.2.5.4 The Pipeline in Overview, 2013
3.3 The Leaders, 2013
3.3.1 Poteligeo (Kyowa Hakko Kirin): First Glycosylated MAb to Market
3.3.1.1 Poteligeo Prospects
3.3.1.2 The Revolution will be Personalised: Simultaneous Approval of Companion Diagnostic for Poteligeo
3.3.2 GA101: The Leading Glyco-Engineered Antibody
3.3.2.1 Can GA101 Take Over From Rituxan?
3.3.2.2 The Battle for the anti-CD20 Market: GA101 as Follow-On
3.3.2.3 Is Improved ADCC Enough to Differentiate GA101?
3.3.2.4 Phase 3 Data for GA101
3.3.2.5 Subcutaneous Rituxan: An Alternative PLM Approach
3.3.3 XmAb 5574 (Xencor): Leading 'Mutant' MAb
3.3.3.1 Clinical Trials Progress for XmAb5574
3.3.3.2 Amino Acid Mutations vs Glycosylation
3.3.3.3 XmAb's 'Diverse Toolbox': The Best Engineering Platform?
3.4 Other Products in the Pipeline, 2013
3.4.1 GA201 (Roche): A Solid Tumour Treatment
3.4.1.1 EGFR: New Drugs for an Old Target
3.4.2 MEDI563 (MedImmune/BioWa): Possible Asthma MAb
3.4.2.1 Next-Generation Antibodies Outside the Oncology Area
3.4.2.2 Other MedImmune/BioWa Respiratory MAbs
3.4.3 MEDI-551 (MedImmune): Option for Cancer and MS
3.4.4 KW-2871 (Life Science Pharmaceuticals): Melanoma Treatment
3.4.5 Roledumab (LFB): Leading French Plasma Firm Enters Engineered Antibodies Segment
3.4.6 AME-133v (Mentrik Biotech): Applied Molecular Evolution Platform
3.4.7 Earlier Stage Candidates, 2013
3.4.8 BIW8962 (Kyowa Hakko Kirin): Myeloma Trial Failure
3.4.9 KHK2298 (Kyowa Hakko Kirin): First Product of the KM Mouse Combined Platform
3.4.10 KHK2804 (Kyowa Hakko Kirin): Targeting Tumour Glycans
3.4.11 KHK2866 (Kyowa Hakko Kirin): HB-EGF Binding Candidate
3.4.12 MDX 1411 (Bristol-Myers Squibb): Kidney Cancer Candidate
3.4.13 MDX 1401 (Bristol-Myers Squibb): Non-Fucosylated MDX
3.4.14 MDX 1342 (Bristol-Myers Squibb): Third Potelligent Medarex Candidate
3.4.15 RG7116 (Roche): Another Addition to the HER Franchise?
3.4.16 GT-MAB2.5GEX (Glycotope): Lead GlycoBody
3.4.17 GT-MAB5.2GEX (Glycotope): Bio-Better Substitute for Erbitux?
3.4.18 GT-MAB7.3GEX (Glycotope): Another Bio-Better Candidate
3.4.19 LFB-R603 (LFB): Another Entrant in the Anti-CD20 Field
3.4.20 XmAb 2513 (Xencor): Phase 1 Completed
3.4.21 MGAH22 (MacroGenics): Another Independent Platform
3.4.22 MGA271 (MacroGenics): Refractory Cancer Treatment
3.4.23 PF-04605412 (Pfizer): Targeting Integrins
3.4.24 Engineered Antibodies in Preclinical Study, 2013
3.5 Drivers and Restraints for Engineered Antibodies, 2013
4. ANTIBODY-DRUG CONJUGATES MARKET 2013-2023
4.1 Antibody-Drug Conjugates: Market Forecast, 2013-2023
4.2 ADCs: Overview of the Field in 2013
4.2.1 Arming Antibodies: Conjugation for Added Potency
4.2.1.1 ADCs: Cytotoxic 'Trojan Horses'
4.2.1.2 Gemtuzumab Ozogamicin: A False Start for the Segment
4.2.1.3 Radioconjugates: Temporarily in Eclipse?
4.2.2 Two Platforms Dominate the Segment
4.2.2.1 Seattle Genetics: Out in Front
4.2.2.2 ImmunoGen: 10 Clinical-Stage Products
4.2.2.3 Other ADC Platforms in Development
4.2.3 The ADC Pipeline, 2013
4.2.3.1 The Biggest Next-Generation Pipeline in 2013
4.2.3.2 Low Duplication of Targets
4.2.3.3 Roche and Bayer Using Both Platforms
4.2.3.4 The ADC Pipeline in Overview, 2013
4.3.Segment Leaders in 2013
4.3.1 Adcetris (Seattle Genetics): First in Class
4.3.1.1 Clinical Data for Adcetris
4.3.1.2 'First HL Approval in 30 Years'
4.3.1.3 Expanding Indications for Adcetris: NHL and Other Lymphomas
4.3.1.4 Commercial Performance of Adcetris to Date: Possible Cost and Supply Line Issues?
4.3.1.5 Implications for the ADC Field
4.3.2 T-DM1 (Roche): First Solid Tumour ADC
4.3.2.1 T-DM1's Bumpy Progress Through Trials
4.3.2.2 Roche's HER2 Franchise Management
4.3.2.3 Patient-Based Pricing
4.3.2.4 T-DM1 Vs GA101 as PLM Strategies
4.3.3 Inotuzumab Ozogamicin (Pfizer): Another Attempt for Wyeth's Technology
4.3.3.1 Clinical Development of Inotuzumab Ozogamicin
4.3.3.2 Pfizer's Biologics Strategy
4.4 Other ADCs in Development, 2013
4.4.1 CDX-011 (Celldex): Completed Phase
4.4.2 RG7593 (Roche): Another Lymphoma Option
4.4.3 RG7596 (Roche): A Rituxan Combination Option?
4.4.4 SAR3419 (Sanofi): Sanofi Programme in Haematological Cancer
4.4.5 Earlier-Stage Candidates, 2013
4.4.6 IMGN901 (ImmunoGen): Lead Solo Candidate for TAP Platform
4.4.7 BT-062 (Biotest): Myeloma ADC
4.4.8 Milatuzumab-Dox (Immunomedics): Traditional Chemotherapeutic Redeployed
4.4.9 RG7450 (Roche): Targeting STEAP1
4.4.10 RG7458, RG7598, RG7599, RG7600 and RG7636 (Roche): Multiple Roche/Seattle Genetics Collaborations in Process
4.4.11 SAR566658 (Sanofi): A Second Sanofi Programme
4.4.12 Labetuzumab-SN-38 (Immunomedics): Colorectal Cancer Treatment
4.4.13 SGN-75 (Seattle Genetics): Unlicensed SeaGen Candidate
4.4.14 SGN-CD19A (Seattle Genetics): Another In-House Programme
4.4.15 AGS-16C3F (Agensys/Seattle Genetics): Astellas Renews Collaboration
4.4.16 ASG-5ME (Agensys/Seattle Genetics): ADC for Proprietary Antigen
4.4.17 ASG-22M6E (Agensys/Seattle Genetics): Solid Tumour Monotherapy
4.4.18 MLN0264 (Millennium/Seattle Genetics): Treatment for Gastrointestinal Cancers
4.4.19 Undisclosed ADC (Abbott/Seattle Genetics): Squamous Cell Tumour Target?
4.4.20 AMG 595 (Amgen): Amgen Joins the ADC Fray
4.4.21 BAY 79-4620 (Bayer Healthcare): Targeting CA9
4.4.22 BAY 94-9343 (Bayer HealthCare): Bayer Plays the Field
4.4.23 PSMA ADC (Progenics Pharmaceuticals): Prostate Cancer Treatment in Development
4.4.24 IMGN529 (ImmunoGen): CD37 Targeting ADC
4.4.25 IMGN853 (ImmunoGen): Ovarian Cancer Treatment Option?
4.4.26 IMGN338 (ImmunoGen): Another Integrin-Targeting Antibody
4.4.27 BIIB015 (Biogen Idec): CRIPTO in the Crosshairs
4.4.28 MDX-1203 (Bristol-Myers Squibb): Conjugating a Prodrug
4.5 Drivers and Restraints for the ADC Market, 2013
5. BISPECIFIC ANTIBODIES MARKET 2013-2023
5.1 Bispecific Antibodies: Market Forecast, 2013-2023
5.2 Bispecific Antibodies: Overview of the Field in 2013
5.2.1 What Can Bispecifics (bisAbs) Do for the Antibody Field?
5.2.1.1 Recombinant Mixtures: Another Dual-Targeting Method
5.2.1.2 Bispecificity: A Concept Whose Time Has Come at Last
5.2.1.3 Removab: A Mark of Progress
5.2.2 A Fertile Area for R&D
5.2.2.1 CD3 FTW: BiTEs and Other Immune-Cell Recruitment Approaches
5.2.2.2 Dual Ligand or Receptor Blockers
5.2.2.3 Recombinant Antibody Mixtures
5.2.3 Assessing the Bispecific Antibodies Pipeline, 2013
5.2.3.1 12 Products in Clinic, 2013
5.2.3.2 Cancer Predominates
5.2.3.3 Amgen Now the Leader
5.2.3.4 Pipeline in Overview
5.3 Two Products First to Phase
5.3.1 Blinatumumab (Amgen): The Bispecific Leader
5.3.1.1 Performance of Blinatumumab to Date
5.3.1.2 A New Option in ALL?
5.3.2 Sym004 (Symphogen): Leading Oncology Mixture
5.3.2.1 Synergistic Mechanisms of Action
5.3.2.2 Merck Deal to Develop Sym004
5.4 Other Bispecific Candidates in 2013
5.4.1 Sym001 (Symphogen): First Recombinant Mixture in Clinic
5.4.2 MT110 (Amgen): A Second BiTE at the Clinic
5.4.3 MEDI 565 (MedImmune/Amgen): Adneocarcinoma Treatment
5.4.4 BAY2010112 (Bayer): Entering the Clinic in Late 2012
5.4.5 MM-111 (Merrimack): ErbB2 and ErbB3 Together
5.4.6 IMCgp100 (Immunocore): First Fruits of IMMTAC Platform
5.4.7 AFM13 (Affimed Therapeutics): Pioneer Tandab
5.4.8 TF2 (Immunomedics): Dock-and-Lock Bispecific for Pretargeted Radioimmunotherapy
5.4.9 Ertumaxomab and FBT A05 (Fresenius): New Products from First-to-Market German Leaders
5.4.10 Bispecific Platforms at a Preclinical Development Stage, 2013
5.4.10.1 BiTE Antibodies in Preclinical Work
5.4.10.2 DART Platform (MacroGenics): A New Competitor in the Clinic?
5.5 Drivers and Restraints for Bispecific Antibodies, 2013
6. ANTIBODY FRAGMENTS AND ANTIBODY-LIKE PROTEINS MARKET 2013-2023
6.1 Antibody Fragments and Antibody-Like Proteins Market Forecast, 2013-2023
6.2 Antibody Fragments and Antibody-Like Proteins Market Overview, 2013
6.2.1 Beyond Fab Fragments: The Future of Small Proteins
6.2.1.1 Overlap Between Small Proteins and Bispecific Antibodies
6.2.1.2 New Technologies for Small Proteins
6.2.1.3 Fragments vs Antibody-Like Proteins
6.2.2 Many Platforms, No Clear Leader
6.2.2.1 Nanobodies: The Largest Platform
6.2.2.2 DARPins: Impacting AMD?
6.2.2.3 Adnectins: Among the Leading Scaffolds
6.2.2.4 Other Technology Platforms in this Segment
6.2.3 Overview of the Pipeline, 2013
6.2.3.1 Five Products in Phase 2, 2013
6.2.3.2 Ophthalmics A Key Target for Small Proteins
6.2.3.3 Ablynx Has a Stake in Six of the Clinical Stage Products
6.2.3.4 Pipeline in Overview, 2013
6.3 Two Segment-Leading Products, 2013
6.3.1 AGN-150998 (Allergan): Long Half-Life, High Binding Specificity
6.3.1.1 Improved Delivery Options
6.3.1.2 Prospects for AGN-150998: Can It Break Into the Wet AMD Segment?
6.3.1.3 Future DARPins
6.3.2 ALX-071(Ablynx): Nebulised Fragment
6.3.2.1 A Successor to Synagis?
6.4 Other Candidates in Development, 2013
6.4.1 Ozoralizumab (Ablynx): Life After Pfizer?
6.4.2 ALX-0061 (Ablynx): Another RA Option
6.4.3 CT-322 (Adnexus): Anti-Angiogenic Scaffold
6.4.4 ESBA105 (Alcon): Leading Naked ScFv
6.4.4.1 ESBATech's Fragment Technology Now Owned by Novartis
6.4.5 ESBA 1008 (Alcon): Another Wet AMD Approach
6.4.6 ATN-192 (Ablynx): PEGylated Plan B for RA
6.4.7 ALX-0141 (Ablynx): Possible Osteoporosis Treatment?
6.4.8 TAS266 (Ablynx): Entering Clinic in 2012
6.4.9 PRS-050 (Pieris): Another VEGF-Blocking Antibody-Like Protein
6.4.9.1 Anticalins: One of the Leading Scaffolds
6.4.9.2 Developing Anticalin Candidates
6.4.9.3 Future Anticalins
6.4.10 GSK1827771 (GlaxoSmithKline): Domantis Legacy Lives On?
6.4.11 GSK1995057 (GlaxoSmithKline): Respiratory Domain Antibody
6.4.11.1 Other GlaxoSmithKline Domain Antibody Programmes
6.4.12 CEP-37247 (Cephalon): Discontinued by Teva
6.4.13 Other Preclinical Platforms in this Segment, 2013
6.4.13.1 UniBodies (Genmab): Eliminating IgG4 Hinge Regions
6.4.13.2 IgNARs (Pfizer): Shark-Derived Antibodies
6.4.13.3 Affibodies (Affibody): Smallest Protein Candidates
6.4.13.4 Fynomers (Covagen): Versatile Binding Proteins
6.4.13.5 Affilins (Scil Proteins): Ubiquitin-Based Molecules
6.5 Drivers and Restraints for Antibody Fragments and Antibody-Like Proteins, 2013
7. BIOSIMILAR ANTIBODIES MARKET, 2013-2023
7.1 Biosimilar Antibodies Market Forecast, 2013-2023
7.2. Biosimilar Antibodies: Overview of the Field, 2013
7.2.1 Biosimilar: Generic or Better?
7.2.1.1 The EU Guidance of 2012
7.2.1.2 The Field After the EU Guidance
7.2.1.3 Challenges Remain in Biosimilar Development
7.2.2 Patent Protection: Key to the Market
7.2.3 Over 80 Products in Development, Mostly Preclinical
7.2.3.1 Multinationals Entering the Sector
7.3 Major Targets for Biosimilar Development, 2013
7.3.1 Biosimilar Substitute for Rituximab: The Biggest Target
7.3.1.1 Potential Players in this Space
7.3.2 Biosimilar Substitute for Herceptin: Celltrion Leads the Way
7.3.3 Biosimilar Substitute for Enbrel: Will Amgen Patent Extension Block the Developers?
7.3.4 Biosimilar Substitute for Remicade: Celltrion Out in Front Again
7.4 Drivers and Restraints for Biosimilar Antibodies, 2013
8. QUALITATIVE INDUSTRY ANALYSIS: DRIVERS AND RESTRAINTS, 2013
8.1 Next Generation Antibody Therapeutics: A Market at the Tipping Point
8.2 Many Pathways to More Potency
8.3 Differentiation will be the Driver
8.4 Biosimilar Antibodies are the Major Catalyst
8.5 Improving Bioanalytics for Next-Generation Products
8.6 A PLM Toolkit for Antibody Therapeutics?
8.7 From Infusion to Eyedrops: New Delivery Systems
8.8 Smashing Down the Entry Barriers: Will Next-Generation Products Throw Open the Market?
8.9 Many Platforms, Many Possibilities
8.10 Which Next-Generation Products Can Co-Exist in the Market?
8.11 Much is Promised but Little Performed, to Date
8.12 Innovation Isn't Everything
8.13 Biosimilar Doubts: How Easily Can the Regulatory Pathway be Crossed?
8.14 Cost of Goods: If We Build the Antibodies, Will They Come?
8.15 The Next-Generation Market's Future Heavily Depends on Breaking Through in Oncology
8.16 Next-Generation Products and Personalised Medicine
9. RESEARCH INTERVIEWS
9.1 Interview with Ivan Horak, Symphogen
9.1.1 Advantages of Antibody Mixtures
9.1.2 Antibody Mixtures for Receptor Degradation
9.1.3 Activating the Immune System
9.1.4 Symphogen Targets and Programmes
9.1.5 Defining Symphogen's Place in the Next-Generation Sector
9.1.6 The Next Ten Years
9.2 Interview with Professor Arne Skerra, Pieris AG
9.2.1 Current 'State of Play' for Alternative Scaffolds
9.2.2 Ophthalmic and Systemic Applications for Scaffolds
9.2.3 Choosing Targets and Differentiating Products
9.2.4 Possible Mechanisms of Action for Antibodies and Scaffolds
9.2.5 The Commoditisation of Antibody Technology
9.2.6 Scaffolds: The Next Wave
10. CONCLUSIONS
10.1 Next-Generation Antibody Therapeutics Industry Growing Rapidly
10.2 ADCs will Remain the Dominant Segment
10.3 More Than 80 Products in Development, With Around Ten Leading Technology Platforms
10.4 These New Approaches Can Rejuvenate the Antibody Therapeutics Market
1.1 Next-Generation Antibody Therapeutics: Market Overview
1.2 Contents of this Report
1.3 Research and Analysis Methods
2. ANTIBODY THERAPEUTICS, PAST, PRESENT AND FUTURE: CLINICAL AND COMMERCIAL OVERVIEW, 2013-2023
2.1 Antibody Therapeutics: Worth More Than $50bn in 2011
2.1.1 Can Antibody Therapeutic Growth Continue? Forecast for the Market, 2013-2023
2.1.2 Next-Generation Antibody Technologies: A Revolution in Waiting
2.1.3 Next-Generation Antibody Therapeutics Will Capture More than 10% of the Market by 2023
2.1.4 Which Segments Will Grow Fastest? Next-Generation Market Forecast Breakdown, 2011-2023
2.2 From First Discoveries to Full Humanisation: The Growth of the Antibody Market
2.2.1 Natural Antibodies: Key to the Immune System
2.2.2 From Serum Therapy to Monoclonal Antibodies (MAbs)
2.2.3 Humanising the MAb
2.2.4 Fabs, Fusion Proteins and Other Variations on the MAb Theme
2.3 The Next Generation Antibody Therapeutics Market: An Overview
2.3.1 Market Shares for Next-Generation Segments, 2011-2023
2.3.1.1 ADCs Lead the Way, 2011-2012
2.3.1.2 CAGR Over 100% for Three Segments, 2011-2016
2.3.1.3 Bispecific Antibodies to Reach 19% Market Shares by, 2017-2023
2.3.2 Next Generation Antibody Therapeutics: Product Analysis
2.3.2.1 Approved Next-Generation Antibody Therapeutics
2.3.2.2 More than 80 Products in Clinic
2.3.3 Oncology: The Major Focus
2.3.4 The Main Targets for Next-Generation Products
2.3.5 Regional Markets for Next-Generation Products
3. ENGINEERED ANTIBODIES MARKET, 2013-2023
3.1 Engineered Antibodies Market Forecast, 2013-2023
3.2 Engineered Antibodies: Overview of the Field in 2011
3.2.1 Antibody Optimisation is the Norm
3.2.2 Engineering for a Real Difference: CDC, ADCC and Half-Life
3.2.3 Ways to Engineer: Glycosylation and Amino Acid Mutations
3.2.4 What are the Platforms?
3.2.4.1 BioWa: Potelligent Removal of Fructose
3.2.4.2 Glycart: GlycoMAB for Extra ADCC
3.2.4.3 Xencor: XmAb Leads Amino Acid Modification Engineering Pipeline
3.2.5 The Pipeline for Engineered Antibodies, 2013
3.2.5.1 25 Candidates in Clinic, 2013
3.2.5.2 CD20 and HER Family Major Targets
3.2.5.3 Kyowa Hakko Kirin Largest Share of Pipeline by Volume
3.2.5.4 The Pipeline in Overview, 2013
3.3 The Leaders, 2013
3.3.1 Poteligeo (Kyowa Hakko Kirin): First Glycosylated MAb to Market
3.3.1.1 Poteligeo Prospects
3.3.1.2 The Revolution will be Personalised: Simultaneous Approval of Companion Diagnostic for Poteligeo
3.3.2 GA101: The Leading Glyco-Engineered Antibody
3.3.2.1 Can GA101 Take Over From Rituxan?
3.3.2.2 The Battle for the anti-CD20 Market: GA101 as Follow-On
3.3.2.3 Is Improved ADCC Enough to Differentiate GA101?
3.3.2.4 Phase 3 Data for GA101
3.3.2.5 Subcutaneous Rituxan: An Alternative PLM Approach
3.3.3 XmAb 5574 (Xencor): Leading 'Mutant' MAb
3.3.3.1 Clinical Trials Progress for XmAb5574
3.3.3.2 Amino Acid Mutations vs Glycosylation
3.3.3.3 XmAb's 'Diverse Toolbox': The Best Engineering Platform?
3.4 Other Products in the Pipeline, 2013
3.4.1 GA201 (Roche): A Solid Tumour Treatment
3.4.1.1 EGFR: New Drugs for an Old Target
3.4.2 MEDI563 (MedImmune/BioWa): Possible Asthma MAb
3.4.2.1 Next-Generation Antibodies Outside the Oncology Area
3.4.2.2 Other MedImmune/BioWa Respiratory MAbs
3.4.3 MEDI-551 (MedImmune): Option for Cancer and MS
3.4.4 KW-2871 (Life Science Pharmaceuticals): Melanoma Treatment
3.4.5 Roledumab (LFB): Leading French Plasma Firm Enters Engineered Antibodies Segment
3.4.6 AME-133v (Mentrik Biotech): Applied Molecular Evolution Platform
3.4.7 Earlier Stage Candidates, 2013
3.4.8 BIW8962 (Kyowa Hakko Kirin): Myeloma Trial Failure
3.4.9 KHK2298 (Kyowa Hakko Kirin): First Product of the KM Mouse Combined Platform
3.4.10 KHK2804 (Kyowa Hakko Kirin): Targeting Tumour Glycans
3.4.11 KHK2866 (Kyowa Hakko Kirin): HB-EGF Binding Candidate
3.4.12 MDX 1411 (Bristol-Myers Squibb): Kidney Cancer Candidate
3.4.13 MDX 1401 (Bristol-Myers Squibb): Non-Fucosylated MDX
3.4.14 MDX 1342 (Bristol-Myers Squibb): Third Potelligent Medarex Candidate
3.4.15 RG7116 (Roche): Another Addition to the HER Franchise?
3.4.16 GT-MAB2.5GEX (Glycotope): Lead GlycoBody
3.4.17 GT-MAB5.2GEX (Glycotope): Bio-Better Substitute for Erbitux?
3.4.18 GT-MAB7.3GEX (Glycotope): Another Bio-Better Candidate
3.4.19 LFB-R603 (LFB): Another Entrant in the Anti-CD20 Field
3.4.20 XmAb 2513 (Xencor): Phase 1 Completed
3.4.21 MGAH22 (MacroGenics): Another Independent Platform
3.4.22 MGA271 (MacroGenics): Refractory Cancer Treatment
3.4.23 PF-04605412 (Pfizer): Targeting Integrins
3.4.24 Engineered Antibodies in Preclinical Study, 2013
3.5 Drivers and Restraints for Engineered Antibodies, 2013
4. ANTIBODY-DRUG CONJUGATES MARKET 2013-2023
4.1 Antibody-Drug Conjugates: Market Forecast, 2013-2023
4.2 ADCs: Overview of the Field in 2013
4.2.1 Arming Antibodies: Conjugation for Added Potency
4.2.1.1 ADCs: Cytotoxic 'Trojan Horses'
4.2.1.2 Gemtuzumab Ozogamicin: A False Start for the Segment
4.2.1.3 Radioconjugates: Temporarily in Eclipse?
4.2.2 Two Platforms Dominate the Segment
4.2.2.1 Seattle Genetics: Out in Front
4.2.2.2 ImmunoGen: 10 Clinical-Stage Products
4.2.2.3 Other ADC Platforms in Development
4.2.3 The ADC Pipeline, 2013
4.2.3.1 The Biggest Next-Generation Pipeline in 2013
4.2.3.2 Low Duplication of Targets
4.2.3.3 Roche and Bayer Using Both Platforms
4.2.3.4 The ADC Pipeline in Overview, 2013
4.3.Segment Leaders in 2013
4.3.1 Adcetris (Seattle Genetics): First in Class
4.3.1.1 Clinical Data for Adcetris
4.3.1.2 'First HL Approval in 30 Years'
4.3.1.3 Expanding Indications for Adcetris: NHL and Other Lymphomas
4.3.1.4 Commercial Performance of Adcetris to Date: Possible Cost and Supply Line Issues?
4.3.1.5 Implications for the ADC Field
4.3.2 T-DM1 (Roche): First Solid Tumour ADC
4.3.2.1 T-DM1's Bumpy Progress Through Trials
4.3.2.2 Roche's HER2 Franchise Management
4.3.2.3 Patient-Based Pricing
4.3.2.4 T-DM1 Vs GA101 as PLM Strategies
4.3.3 Inotuzumab Ozogamicin (Pfizer): Another Attempt for Wyeth's Technology
4.3.3.1 Clinical Development of Inotuzumab Ozogamicin
4.3.3.2 Pfizer's Biologics Strategy
4.4 Other ADCs in Development, 2013
4.4.1 CDX-011 (Celldex): Completed Phase
4.4.2 RG7593 (Roche): Another Lymphoma Option
4.4.3 RG7596 (Roche): A Rituxan Combination Option?
4.4.4 SAR3419 (Sanofi): Sanofi Programme in Haematological Cancer
4.4.5 Earlier-Stage Candidates, 2013
4.4.6 IMGN901 (ImmunoGen): Lead Solo Candidate for TAP Platform
4.4.7 BT-062 (Biotest): Myeloma ADC
4.4.8 Milatuzumab-Dox (Immunomedics): Traditional Chemotherapeutic Redeployed
4.4.9 RG7450 (Roche): Targeting STEAP1
4.4.10 RG7458, RG7598, RG7599, RG7600 and RG7636 (Roche): Multiple Roche/Seattle Genetics Collaborations in Process
4.4.11 SAR566658 (Sanofi): A Second Sanofi Programme
4.4.12 Labetuzumab-SN-38 (Immunomedics): Colorectal Cancer Treatment
4.4.13 SGN-75 (Seattle Genetics): Unlicensed SeaGen Candidate
4.4.14 SGN-CD19A (Seattle Genetics): Another In-House Programme
4.4.15 AGS-16C3F (Agensys/Seattle Genetics): Astellas Renews Collaboration
4.4.16 ASG-5ME (Agensys/Seattle Genetics): ADC for Proprietary Antigen
4.4.17 ASG-22M6E (Agensys/Seattle Genetics): Solid Tumour Monotherapy
4.4.18 MLN0264 (Millennium/Seattle Genetics): Treatment for Gastrointestinal Cancers
4.4.19 Undisclosed ADC (Abbott/Seattle Genetics): Squamous Cell Tumour Target?
4.4.20 AMG 595 (Amgen): Amgen Joins the ADC Fray
4.4.21 BAY 79-4620 (Bayer Healthcare): Targeting CA9
4.4.22 BAY 94-9343 (Bayer HealthCare): Bayer Plays the Field
4.4.23 PSMA ADC (Progenics Pharmaceuticals): Prostate Cancer Treatment in Development
4.4.24 IMGN529 (ImmunoGen): CD37 Targeting ADC
4.4.25 IMGN853 (ImmunoGen): Ovarian Cancer Treatment Option?
4.4.26 IMGN338 (ImmunoGen): Another Integrin-Targeting Antibody
4.4.27 BIIB015 (Biogen Idec): CRIPTO in the Crosshairs
4.4.28 MDX-1203 (Bristol-Myers Squibb): Conjugating a Prodrug
4.5 Drivers and Restraints for the ADC Market, 2013
5. BISPECIFIC ANTIBODIES MARKET 2013-2023
5.1 Bispecific Antibodies: Market Forecast, 2013-2023
5.2 Bispecific Antibodies: Overview of the Field in 2013
5.2.1 What Can Bispecifics (bisAbs) Do for the Antibody Field?
5.2.1.1 Recombinant Mixtures: Another Dual-Targeting Method
5.2.1.2 Bispecificity: A Concept Whose Time Has Come at Last
5.2.1.3 Removab: A Mark of Progress
5.2.2 A Fertile Area for R&D
5.2.2.1 CD3 FTW: BiTEs and Other Immune-Cell Recruitment Approaches
5.2.2.2 Dual Ligand or Receptor Blockers
5.2.2.3 Recombinant Antibody Mixtures
5.2.3 Assessing the Bispecific Antibodies Pipeline, 2013
5.2.3.1 12 Products in Clinic, 2013
5.2.3.2 Cancer Predominates
5.2.3.3 Amgen Now the Leader
5.2.3.4 Pipeline in Overview
5.3 Two Products First to Phase
5.3.1 Blinatumumab (Amgen): The Bispecific Leader
5.3.1.1 Performance of Blinatumumab to Date
5.3.1.2 A New Option in ALL?
5.3.2 Sym004 (Symphogen): Leading Oncology Mixture
5.3.2.1 Synergistic Mechanisms of Action
5.3.2.2 Merck Deal to Develop Sym004
5.4 Other Bispecific Candidates in 2013
5.4.1 Sym001 (Symphogen): First Recombinant Mixture in Clinic
5.4.2 MT110 (Amgen): A Second BiTE at the Clinic
5.4.3 MEDI 565 (MedImmune/Amgen): Adneocarcinoma Treatment
5.4.4 BAY2010112 (Bayer): Entering the Clinic in Late 2012
5.4.5 MM-111 (Merrimack): ErbB2 and ErbB3 Together
5.4.6 IMCgp100 (Immunocore): First Fruits of IMMTAC Platform
5.4.7 AFM13 (Affimed Therapeutics): Pioneer Tandab
5.4.8 TF2 (Immunomedics): Dock-and-Lock Bispecific for Pretargeted Radioimmunotherapy
5.4.9 Ertumaxomab and FBT A05 (Fresenius): New Products from First-to-Market German Leaders
5.4.10 Bispecific Platforms at a Preclinical Development Stage, 2013
5.4.10.1 BiTE Antibodies in Preclinical Work
5.4.10.2 DART Platform (MacroGenics): A New Competitor in the Clinic?
5.5 Drivers and Restraints for Bispecific Antibodies, 2013
6. ANTIBODY FRAGMENTS AND ANTIBODY-LIKE PROTEINS MARKET 2013-2023
6.1 Antibody Fragments and Antibody-Like Proteins Market Forecast, 2013-2023
6.2 Antibody Fragments and Antibody-Like Proteins Market Overview, 2013
6.2.1 Beyond Fab Fragments: The Future of Small Proteins
6.2.1.1 Overlap Between Small Proteins and Bispecific Antibodies
6.2.1.2 New Technologies for Small Proteins
6.2.1.3 Fragments vs Antibody-Like Proteins
6.2.2 Many Platforms, No Clear Leader
6.2.2.1 Nanobodies: The Largest Platform
6.2.2.2 DARPins: Impacting AMD?
6.2.2.3 Adnectins: Among the Leading Scaffolds
6.2.2.4 Other Technology Platforms in this Segment
6.2.3 Overview of the Pipeline, 2013
6.2.3.1 Five Products in Phase 2, 2013
6.2.3.2 Ophthalmics A Key Target for Small Proteins
6.2.3.3 Ablynx Has a Stake in Six of the Clinical Stage Products
6.2.3.4 Pipeline in Overview, 2013
6.3 Two Segment-Leading Products, 2013
6.3.1 AGN-150998 (Allergan): Long Half-Life, High Binding Specificity
6.3.1.1 Improved Delivery Options
6.3.1.2 Prospects for AGN-150998: Can It Break Into the Wet AMD Segment?
6.3.1.3 Future DARPins
6.3.2 ALX-071(Ablynx): Nebulised Fragment
6.3.2.1 A Successor to Synagis?
6.4 Other Candidates in Development, 2013
6.4.1 Ozoralizumab (Ablynx): Life After Pfizer?
6.4.2 ALX-0061 (Ablynx): Another RA Option
6.4.3 CT-322 (Adnexus): Anti-Angiogenic Scaffold
6.4.4 ESBA105 (Alcon): Leading Naked ScFv
6.4.4.1 ESBATech's Fragment Technology Now Owned by Novartis
6.4.5 ESBA 1008 (Alcon): Another Wet AMD Approach
6.4.6 ATN-192 (Ablynx): PEGylated Plan B for RA
6.4.7 ALX-0141 (Ablynx): Possible Osteoporosis Treatment?
6.4.8 TAS266 (Ablynx): Entering Clinic in 2012
6.4.9 PRS-050 (Pieris): Another VEGF-Blocking Antibody-Like Protein
6.4.9.1 Anticalins: One of the Leading Scaffolds
6.4.9.2 Developing Anticalin Candidates
6.4.9.3 Future Anticalins
6.4.10 GSK1827771 (GlaxoSmithKline): Domantis Legacy Lives On?
6.4.11 GSK1995057 (GlaxoSmithKline): Respiratory Domain Antibody
6.4.11.1 Other GlaxoSmithKline Domain Antibody Programmes
6.4.12 CEP-37247 (Cephalon): Discontinued by Teva
6.4.13 Other Preclinical Platforms in this Segment, 2013
6.4.13.1 UniBodies (Genmab): Eliminating IgG4 Hinge Regions
6.4.13.2 IgNARs (Pfizer): Shark-Derived Antibodies
6.4.13.3 Affibodies (Affibody): Smallest Protein Candidates
6.4.13.4 Fynomers (Covagen): Versatile Binding Proteins
6.4.13.5 Affilins (Scil Proteins): Ubiquitin-Based Molecules
6.5 Drivers and Restraints for Antibody Fragments and Antibody-Like Proteins, 2013
7. BIOSIMILAR ANTIBODIES MARKET, 2013-2023
7.1 Biosimilar Antibodies Market Forecast, 2013-2023
7.2. Biosimilar Antibodies: Overview of the Field, 2013
7.2.1 Biosimilar: Generic or Better?
7.2.1.1 The EU Guidance of 2012
7.2.1.2 The Field After the EU Guidance
7.2.1.3 Challenges Remain in Biosimilar Development
7.2.2 Patent Protection: Key to the Market
7.2.3 Over 80 Products in Development, Mostly Preclinical
7.2.3.1 Multinationals Entering the Sector
7.3 Major Targets for Biosimilar Development, 2013
7.3.1 Biosimilar Substitute for Rituximab: The Biggest Target
7.3.1.1 Potential Players in this Space
7.3.2 Biosimilar Substitute for Herceptin: Celltrion Leads the Way
7.3.3 Biosimilar Substitute for Enbrel: Will Amgen Patent Extension Block the Developers?
7.3.4 Biosimilar Substitute for Remicade: Celltrion Out in Front Again
7.4 Drivers and Restraints for Biosimilar Antibodies, 2013
8. QUALITATIVE INDUSTRY ANALYSIS: DRIVERS AND RESTRAINTS, 2013
8.1 Next Generation Antibody Therapeutics: A Market at the Tipping Point
8.2 Many Pathways to More Potency
8.3 Differentiation will be the Driver
8.4 Biosimilar Antibodies are the Major Catalyst
8.5 Improving Bioanalytics for Next-Generation Products
8.6 A PLM Toolkit for Antibody Therapeutics?
8.7 From Infusion to Eyedrops: New Delivery Systems
8.8 Smashing Down the Entry Barriers: Will Next-Generation Products Throw Open the Market?
8.9 Many Platforms, Many Possibilities
8.10 Which Next-Generation Products Can Co-Exist in the Market?
8.11 Much is Promised but Little Performed, to Date
8.12 Innovation Isn't Everything
8.13 Biosimilar Doubts: How Easily Can the Regulatory Pathway be Crossed?
8.14 Cost of Goods: If We Build the Antibodies, Will They Come?
8.15 The Next-Generation Market's Future Heavily Depends on Breaking Through in Oncology
8.16 Next-Generation Products and Personalised Medicine
9. RESEARCH INTERVIEWS
9.1 Interview with Ivan Horak, Symphogen
9.1.1 Advantages of Antibody Mixtures
9.1.2 Antibody Mixtures for Receptor Degradation
9.1.3 Activating the Immune System
9.1.4 Symphogen Targets and Programmes
9.1.5 Defining Symphogen's Place in the Next-Generation Sector
9.1.6 The Next Ten Years
9.2 Interview with Professor Arne Skerra, Pieris AG
9.2.1 Current 'State of Play' for Alternative Scaffolds
9.2.2 Ophthalmic and Systemic Applications for Scaffolds
9.2.3 Choosing Targets and Differentiating Products
9.2.4 Possible Mechanisms of Action for Antibodies and Scaffolds
9.2.5 The Commoditisation of Antibody Technology
9.2.6 Scaffolds: The Next Wave
10. CONCLUSIONS
10.1 Next-Generation Antibody Therapeutics Industry Growing Rapidly
10.2 ADCs will Remain the Dominant Segment
10.3 More Than 80 Products in Development, With Around Ten Leading Technology Platforms
10.4 These New Approaches Can Rejuvenate the Antibody Therapeutics Market
LIST OF TABLES
Table 2.1 Global Antibody Therapeutics Market: Leading Products, Revenues ($bn), Market Shares (%), 2011
Table 2.2 Global Antibody Therapeutics Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 2.3 Global Antibody Therapeutics Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2023
Table 2.4 Next-Generation Antibody Therapeutics Market: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 2.5 Next-Generation Antibody Therapeutics Market: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 2.6 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 2.7 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 2.8 Regions of an Antibody
Table 2.9 Natural Antibody Mechanisms of Action
Table 2.10 Approved Murine mAbs, 2013
Table 2.11 Approved Chimeric MAbs, 2013
Table 2.12 Approved Humanised MAbs, 2013
Table 2.13 Approved Fully-Human MAbs, 2013
Table 2.14 Approved Fab Fragments, 2013
Table 2.15 Approved Fusion Proteins, 2013
Table 2.16 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), Market Shares (%), 2011-2012
Table 2.17 Approved Next-Generation Antibody Therapeutics, 2007-2012
Table 2.18 Phase 3 Pipeline for Next-Generation Antibody Therapeutics, 2013
Table 2.19 Popular Antigenic Targets for Next-Generation Antibody Therapeutics, 2013
Table 3.1 Engineered Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016
Table 3.2 Engineered Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023
Table 3.3 Some Common Antibody Enhancements, 2013
Table 3.4 Selected Products from the Potelligent Platform, 2013
Table 3.5 Selected Products from the Glycart Platform, 2013
Table 3.6 Selected Products from the XmAb Platform, 2013
Table 3.7 Engineered Antibodies Pipeline, 2013
Table 3.8 Comparative Possibilities of Amino Acid Mutation and Glycoengineering for Fc Engineering, 2013
Table 3.9 Selected Engineered Antibodies Pipeline, Phase 2, 2013
Table 3.10 Selected Engineered Antibodies Pipeline, Pre-Phase 2, 2013
Table 3.11 Selected Engineered Antibodies Pipeline, Preclinical, 2013
Table 4.1 ADC Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016
Table 4.2 ADC Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023
Table 4.3 Selected Products from the Seattle Genetics Platform, 2013
Table 4.4 Selected Products from the TAP Platform, 2013
Table 4.5 Selected Other Platforms Relevant to ADC Segment, 2013
Table 4.6 ADCs Pipeline, 2013
Table 4.7 Selected ADCs Pipeline, Phase 2, 2013
Table 4.8 Selected ADCs Pipeline, Pre-Phase 2, 2013
Table 5.1 Bispecific Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016
Table 5.2 Bispecific Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023
Table 5.3 Selected Products from BiTE Platform, 2013
Table 5.4 Selected Other Platforms for Bispecific Molecules, 2013
Table 5.5 Selected Recombinant Antibody Mixtures Pipeline, 2013
Table 5.6 Bispecific Antibody Clinical Pipeline Overview, 2013
Table 5.7 Bispecific Antibody Clinical Pipeline: Phase 2 and Earlier, 2013
Table 6.1 Antibody Fragments and Antibody-Like Proteins Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016
Table 6.2 Antibody Fragments and Antibody-Like Proteins Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023
Table 6.3 Antibody Fragments and Antibody-Like Proteins Segment: Selected Preclinical Platforms, 2013
Table 6.4 Antibody Fragments and Antibody-Like Proteins Segment: Clinical Pipeline, 2013
Table 6.5 Antibody Fragments and Antibody-Like Proteins Segment: Phase 2 and Earlier Clinical Pipeline, 2013
Table 7.1 Biosimilar Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016
Table 7.2 Biosimilar Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023
Table 7.3 Leading Antibody Therapeutics: Patent Expiries, 2013-2019
Table 7.4 Selected Biosimilar Antibodies Clinical Pipeline, 2013
Table 2.1 Global Antibody Therapeutics Market: Leading Products, Revenues ($bn), Market Shares (%), 2011
Table 2.2 Global Antibody Therapeutics Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 2.3 Global Antibody Therapeutics Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2023
Table 2.4 Next-Generation Antibody Therapeutics Market: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 2.5 Next-Generation Antibody Therapeutics Market: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 2.6 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 2.7 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 2.8 Regions of an Antibody
Table 2.9 Natural Antibody Mechanisms of Action
Table 2.10 Approved Murine mAbs, 2013
Table 2.11 Approved Chimeric MAbs, 2013
Table 2.12 Approved Humanised MAbs, 2013
Table 2.13 Approved Fully-Human MAbs, 2013
Table 2.14 Approved Fab Fragments, 2013
Table 2.15 Approved Fusion Proteins, 2013
Table 2.16 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), Market Shares (%), 2011-2012
Table 2.17 Approved Next-Generation Antibody Therapeutics, 2007-2012
Table 2.18 Phase 3 Pipeline for Next-Generation Antibody Therapeutics, 2013
Table 2.19 Popular Antigenic Targets for Next-Generation Antibody Therapeutics, 2013
Table 3.1 Engineered Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016
Table 3.2 Engineered Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023
Table 3.3 Some Common Antibody Enhancements, 2013
Table 3.4 Selected Products from the Potelligent Platform, 2013
Table 3.5 Selected Products from the Glycart Platform, 2013
Table 3.6 Selected Products from the XmAb Platform, 2013
Table 3.7 Engineered Antibodies Pipeline, 2013
Table 3.8 Comparative Possibilities of Amino Acid Mutation and Glycoengineering for Fc Engineering, 2013
Table 3.9 Selected Engineered Antibodies Pipeline, Phase 2, 2013
Table 3.10 Selected Engineered Antibodies Pipeline, Pre-Phase 2, 2013
Table 3.11 Selected Engineered Antibodies Pipeline, Preclinical, 2013
Table 4.1 ADC Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016
Table 4.2 ADC Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023
Table 4.3 Selected Products from the Seattle Genetics Platform, 2013
Table 4.4 Selected Products from the TAP Platform, 2013
Table 4.5 Selected Other Platforms Relevant to ADC Segment, 2013
Table 4.6 ADCs Pipeline, 2013
Table 4.7 Selected ADCs Pipeline, Phase 2, 2013
Table 4.8 Selected ADCs Pipeline, Pre-Phase 2, 2013
Table 5.1 Bispecific Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016
Table 5.2 Bispecific Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023
Table 5.3 Selected Products from BiTE Platform, 2013
Table 5.4 Selected Other Platforms for Bispecific Molecules, 2013
Table 5.5 Selected Recombinant Antibody Mixtures Pipeline, 2013
Table 5.6 Bispecific Antibody Clinical Pipeline Overview, 2013
Table 5.7 Bispecific Antibody Clinical Pipeline: Phase 2 and Earlier, 2013
Table 6.1 Antibody Fragments and Antibody-Like Proteins Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016
Table 6.2 Antibody Fragments and Antibody-Like Proteins Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023
Table 6.3 Antibody Fragments and Antibody-Like Proteins Segment: Selected Preclinical Platforms, 2013
Table 6.4 Antibody Fragments and Antibody-Like Proteins Segment: Clinical Pipeline, 2013
Table 6.5 Antibody Fragments and Antibody-Like Proteins Segment: Phase 2 and Earlier Clinical Pipeline, 2013
Table 7.1 Biosimilar Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016
Table 7.2 Biosimilar Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023
Table 7.3 Leading Antibody Therapeutics: Patent Expiries, 2013-2019
Table 7.4 Selected Biosimilar Antibodies Clinical Pipeline, 2013
Bispecific Antibodies Market 2013-2023
This chapter evaluates the bispecifics market, assessing the many approaches under development for achieving dual or multiple targeting with antibody therapeutics. Detailed profiles of blinatumumab and Sym001 are supplied, and ten other clinical-stage candidates and several preclinical technology platforms are studied. A forecast for the segment for 2013-2023 is provided.
Bispecific Antibodies: Market Forecast, 2013-2023
In 2011, the bispecific antibodies market was worth $4m, all of which derived from the only currently-approved product, Removab (catumaxomab), marketed by Fresenius. Visiongain anticipates limited future growth for Removab, with Fresenius targeting its gradual take-up as a standard therapy for malignant ascites in the mid-term. With no other bispecific products further advanced than phase 2 clinical trials by Q1 2013, visiongain anticipates limited growth for the segment to 2016. By 2016, segment revenues will have reached $16m, with a CAGR of 32%, but the segment will by this point represent less than 1% of all next-generation antibody therapeutic revenues.
The coming of BiTE antibodies and other advanced platform technologies to the market will spur the segment to a six-year CAGR of 60% by the end of 2023, with revenues reaching $2,350m (a 70% CAGR for the forecast period overall). This will be the strongest performance by any segment in the second half of the forecast period, and will see bispecific antibodies capture 19% of the nextgeneration antibody therapeutics market by the end of 2023.
